Beigene, Ltd. (NASDAQ:ONC – Get Free Report) COO Xiaobin Wu sold 21,267 shares of Beigene stock in a transaction on Thursday, February 20th. The shares were sold at an average price of $240.07, for a total value of $5,105,568.69. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.
Xiaobin Wu also recently made the following trade(s):
- On Tuesday, February 18th, Xiaobin Wu sold 30,654 shares of Beigene stock. The shares were sold at an average price of $240.74, for a total value of $7,379,643.96.
Beigene Stock Up 3.2 %
Shares of ONC stock traded up $7.51 during mid-day trading on Thursday, hitting $244.20. 758,979 shares of the stock traded hands, compared to its average volume of 354,999. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93. The stock has a market cap of $23.90 billion, a PE ratio of -29.64, a price-to-earnings-growth ratio of 9.50 and a beta of 0.63. Beigene, Ltd. has a twelve month low of $126.97 and a twelve month high of $248.16.
About Beigene
BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
Recommended Stories
- Five stocks we like better than Beigene
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Ray Dalio’s Bridgewater Loaded Up on These Stocks in Q4 2024
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Walmart Faces Tariff Headwinds, Consumer Trends Remain Positive
- Asset Allocation: The Key to a Successful Portfolio. Are You Paying Attention to Yours?
- Tesla: 2 Reasons to Buy, 1 Reason to Run
Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.
